Abstract:Age-dependent neurodegenerative diseases progressively form aggregates containing both shared components (e.g., TDP-43, phosphorylated tau) and proteins specific to each disease. We investigated whether diverse neuropathies might have additional aggregation-prone proteins in common, discoverable by proteomics. Caenorhabditis elegans expressing unc-54p/Q40::YFP, a model of polyglutamine array diseases such as Huntington's, accrues aggregates in muscle 2-6days posthatch. These foci, isolated on antibody-coupled magnetic beads, were characterized by high-resolution mass spectrometry. Three Q40::YFP-associated proteins were inferred to promote aggregation and cytotoxicity, traits reduced or delayed by their RNA interference knockdown. These RNAi treatments also retarded aggregation/cytotoxicity in Alzheimer's disease models, nematodes with muscle or pan-neuronal A(1-42) expression and behavioral phenotypes. The most abundant aggregated proteins are glutamine/asparagine-rich, favoring hydrophobic interactions with other random-coil domains. A particularly potent modulator of aggregation, CRAM-1/HYPK, contributed <1% of protein aggregate peptides, yet its knockdown reduced Q40::YFP aggregates 7286% (P<10(-6)). In worms expressing A(1-42), knockdown of cram-1 reduced -amyloid 60% (P<0.002) and slowed age-dependent paralysis >30% (P<10(-6)). In wild-type worms, cram-1 knockdown reduced aggregation and extended lifespan, but impaired early reproduction. Protection against seeded aggregates requires proteasome function, implying that normal CRAM-1 levels promote aggregation by interfering with proteasomal degradation of misfolded proteins. Molecular dynamic modeling predicts spontaneous and stable interactions of CRAM-1 (or human orthologs) with ubiquitin, and we verified that CRAM-1 reduces degradation of a tagged-ubiquitin reporter. We propose that CRAM-1 exemplifies a class of primitive chaperones that are initially protective and highly beneficial for early reproduction, but ultimately impair aggregate clearance and limit longevity.

Big versus small: The impact of aggregate size in disease

Molecular Simulations of Amyloid Structures, Toxicity, and Inhibition

Proteins in Aggregates Functionally Impact Multiple Neurodegenerative Disease Models by Forming Proteasome-Blocking Complexes

Kinetic models reveal the interplay of protein production and aggregation

Computational studies of protein aggregation mediated by amyloid: Fibril elongation and secondary nucleation

Molecular determinants of protein pathogenicity at the single-aggregate level

Computational simulations of the early steps of protein aggregation.

Protein Aggregation: Opposing Effects of Chaperones and Crowding

Computational Simulations of the Early Steps of Protein Aggregation

Soluble protein oligomers as emerging toxins in alzheimer's and other amyloid diseases

Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.

Influence of Nanoparticle Size and Shape on Oligomer Formation of an Amyloidogenic Peptide

Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer’s Disease, Parkinson’s Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis

The influence of Zwitterionic and anionic phospholipids on protein aggregation

A Kinetic Study of Amyloid Formation

Role of electrostatic interactions in amyloid beta-protein (Abeta) oligomer formation: A discrete molecular dynamics study

Amyloid Aggregation: Role of Biological Membranes and the Aggregate-Membrane System

Factors influencing amyloid fibril formation

Model for competing pathways in protein-aggregation: role of membrane bound proteins

Statistical Mechanical Approach to Protein Aggregations

Aggregation mechanisms and molecular structures of amyloid‐β in Alzheimer's disease